Ensuring medication ingestion without altering existing medication regimen

项目总结 在美国，约有83.5万人生活在辅助生活设施中，其中50%以上 那些患有某种形式的痴呆症或认知障碍的人。那些生活在受助家庭的平均成本 生活设施是每月4050美元，而记忆护理平均每月增加1250美元。 多奈哌齐、加兰他明和利瓦斯明等药物的进展已被证明是有帮助的 管理甚至逆转一些痴呆症症状，但这些药物除非有效，否则不会有效 定期服用。减缓痴呆症的发展可以延长人的生存能力 独立的。虽然使用泡罩包装和药盒的设计是为了帮助确保患者服用 在处方的基础上，这些技术报告了摄取的意图，并且通常不提供任何 可以由家庭以外的其他人监控的反馈。鉴于5300万美国公民已经超过 退休年龄和70%的人在一生中将需要某种形式的长期护理，显然 除非采取替代解决方案，否则管理这一疾病的成本将继续增长。 在拨款的第一阶段，我们建议通过建立以家庭为基础的 摄取监测系统，可以检测家庭内的药物摄取，而不是要求用户 佩戴ID-Cap读卡器。ID-Cap系统目前的设计是通过发送一个小的 当摄取ID-Cap时，从人的胃内发出的无线电信号。现有系统会检测到这些 使用吊带式读卡器发出信号。由于这些患者可能忘记使用阅读器，我们建议创建一个 新的读卡器设计，使用改进的天线设计，可以从房间的另一边“听到”摄取的声音 和信号处理。为了确保检测到患者是否在不同的房间服药，网状网络 的读卡器可以确保信号被检测到并转发到现有的基于云的 监控平台。在第一阶段，我们提出了两个具体目标。 目标1-创建基于墙上插头的网络阅读器原型 利用我们开发现有ID-Cap可穿戴阅读器的经验，我们将设计新一代 阅读器将能够检测到房间内的摄取，而不是要求用户佩戴阅读器。这个 捕获的信号将通过网状网络转发到确保传输到云的基站 存储库，以便护理人员可以监控实际摄取事件，并在需要时进行干预。 目标2--在3个模拟环境中评估新系统的有效性和可接受性 使用原型基站和联网阅读器，我们将评估在三种情况下检测信号的能力 不同的家庭配置。此反馈将有助于通知安装配置设计有关 最佳读卡器数量和位置。对痴呆症患者和他们的照顾者的采访将告知 可接受性。

PROJECT SUMMARY In the US, approximately 835,000 persons are living in assisted living facilities with more than 50 percent of those having some form of dementia or cognitive impairment. The average cost of those living in assisted living facilities is $4050 per month, with memory care increasing this cost by an average of $1250 per month. Advancements in medications such as Donepezil, Galantamine, and Rivastigmine have been shown to help manage and even reverse some dementia symptoms, but these medications are not effective unless they are taken on a regular basis. Slowing the progression of dementia can prolong the ability of persons to live independently. While the use of blister packs and pill boxes are designed to help ensure that patients are taking medications on a prescribed basis, these technologies report intent to ingest and often do not provide any feedback that can be monitored by others outside the home. Given that 53 million US citizens are already past retirement age and that 70 percent will require some form of long-term care in their lifetime, it is clear that the cost of managing this disease will continue to grow unless alternative solutions are put in place. In Phase I of the grant we propose to enhance the FDA cleared ID-Cap system by building a home-based ingestion monitoring system that can detect medication ingestions within the home instead of requiring a user to wear an ID-Cap Reader. The ID-Cap system is currently designed to detect ingestions by sending out a small radio signal from within a person's stomach when an ID-Cap is ingested. The existing system detects these signals using a lanyard-style reader. As these patients may forget to use the reader, we propose to create a new reader design that can “hear” the ingestion from across the room using improvements in antenna design and signal processing. To ensure detection if a patient takes their medication in different rooms, a mesh network of readers placed in the home can ensure that the signal is detected and forwarded to the existing cloud-based monitoring platform. In Phase I, we propose two specific aims. Aim 1 – Create a prototype wall-plug based networked reader Leveraging our experience developing the existing ID-Cap wearable reader, we will design a new generation reader that will be able to detect ingestions within a room instead of requiring the user to wear a reader. The captured signals will be forwarded across a mesh network to a base station that ensures delivery to a cloud repository so that care providers can monitor actual ingestion events and intervene if needed. Aim 2 – Evaluate effectiveness and acceptability of the new system in 3 simulated environments Using the prototyped base station and networked readers, we will evaluate the ability to detect signals in three different home configurations. This feedback will help inform installation configuration designs regarding the optimal number and placement of readers. Interviews with persons with dementia and their caregivers will inform acceptability.